Cargando…

Effectiveness and safety of recombinant activated factor

Detalles Bibliográficos
Autores principales:	Echarri González, G, Lafuente, A, Hernández, M, Moncada, R, Rodríguez, J, Calderón, R, Hidalgo, F, Monedero, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092545/ http://dx.doi.org/10.1186/cc4517

Ejemplares similares

Safety of activated recombinant factor VII in patients with circulatory assist devices
por: Schneider, AS, et al.
Publicado: (2009)

Recombinant activated factor VII for the treatment of bleeding in abdominal surgery and cardiac surgery
por: Michalska, G, et al.
Publicado: (2009)

Predicting response to recombinant activated factor VIIa administration in the critically ill
por: Pugh, R, et al.
Publicado: (2008)

Treatment of obstetric hemorrhage with recombinant activated factor VII
por: Czuprynski, P, et al.
Publicado: (2009)

Recombinant activated factor VII treatment of severe bleeding in cardiac surgery patients: a retrospective analysis of dosing, and efficacy and safety outcomes
por: Liebl, M, et al.
Publicado: (2007)

Pharmacokinetics, safety and tolerability of human recombinant alkaline phosphatase in healthy volunteers
por: Peters, E, et al.
Publicado: (2015)

Two years experience with low-dose recombined activated factor VII treatment of non-haemophilic patients
por: Michalska, G, et al.
Publicado: (2006)

Safety and effectiveness of recombinant human growth hormone replacement in postoperative craniopharyngioma children
por: Zheng, Zhang-qian, et al.
Publicado: (2013)

Use of recombinant activated factor VII after paediatric cardiac surgery
por: Kharkin, A, et al.
Publicado: (2006)

Guidelines-associated decrease in mortality with recombinant activated factor VII for refractory hemorrhage
por: Schneider, AS, et al.
Publicado: (2009)

Cost-effectiveness analysis of recombinant activated factor VII as adjunctive therapy for bleeding control in severely injured trauma patients in Germany
por: Rossaint, R, et al.
Publicado: (2006)

Activated recombinant factor VII in management of bleeding in patients with thrombocytopenia
por: Shulutko, E, et al.
Publicado: (2006)

Recombinant activated factor VII: does it really save lives?
por: Edke, U
Publicado: (2009)

Thromboembolic risks of recombinant factor VIIa use in warfarin-associated intracranial hemorrhage
por: Chou, S, et al.
Publicado: (2011)

Efficacy of recombinant activated factor VII in the management of severe hemorrhage following cardiac surgery
por: Trecova, N, et al.
Publicado: (2006)

Efficacy of activated recombinant factor VII (rFVIIa; NovoSeven(®)) in cirrhotic patients with upper gastrointestinal bleeding: a randomised placebo-controlled double-blind multicenter trial
por: Thabut, D, et al.
Publicado: (2004)

The use of activated recombinant coagulation factor VII in patients undergoing major reconstruction surgery for traumatic fracture pelvis or pelvis and acetabulum: a double-blind, randomised, placebo-controlled trial
por: Raobaikady, R, et al.
Publicado: (2005)

The use of recombinant factor VIIa as a haemostatic agent in ICU patients
por: Vernikos, P, et al.
Publicado: (2004)

Nucleotidyl cyclase activity of recombinant soluble guanylyl cyclase
por: Rauch, Kerstin, et al.
Publicado: (2009)

Recombinant human tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and antibacterial effects in murine pneumococcal pneumonia
por: Boogaard, F van den, et al.
Publicado: (2009)

P19-53 LB. Priming with recombinant BCG expressing HIV-1 Gag or RT and boosting with recombinant MVA induces an effective immune response in mice
por: Stutz, H, et al.
Publicado: (2009)

Patient safety in ICUs: adverse events characterization and potential risk factors
por: Zambon, L, et al.
Publicado: (2011)

P10-02. Toll-like receptor activation profiles of wild-type, recombinant, and mutant Lactobacillus: implications for vaccine design
por: Stoeker, L, et al.
Publicado: (2009)

Does recombinant factor VIIa change the inflammatory response to trauma? Preliminary results of inflammatory biomarkers in critically ill trauma patients
por: Lissauer, M, et al.
Publicado: (2006)

Recombinant trail: a synergistic effect in myeloid leukemias
por: Carvalho, Filipa, et al.
Publicado: (2010)

Evaluation of the role of recombinant activated factor VII (NovoSeven) as a rescue haemostatic therapy in postcardiopulmonary bypass surgical patients
por: Chen, Z, et al.
Publicado: (2007)

Analysis of the off-licence use of recombinant activated factor VII for patients with uncontrolled haemorrhage in a UK tertiary referral hospital
por: Spivey, M, et al.
Publicado: (2009)

Gene expression level: is it an important factor in codon optimization for overexpression of recombinant proteins?
por: Ramos, Juliana da Costa, et al.
Publicado: (2014)

Cardiopulmonary bypass and recombinant plasminogen activator for treatment of experimental fatal pulmonary embolism
por: Kjærgaard, B, et al.
Publicado: (2007)

Effects of recombinant surfactant protein C and elastase inhibitor on neutrophil apoptosis
por: Pravinkumar, E, et al.
Publicado: (2004)

Recombinant human erythropoietin therapy in critically ill patients
por: Georgopoulos, D, et al.
Publicado: (2005)

Recombinant biosynthesis of functional human growth hormone and coagulation factor IX in transgenic soybean seeds
por: da Cunha, Nicolau Brito, et al.
Publicado: (2014)

Determination of occupational safety and health factors in young workers
por: Nory Ghere Aghag, Ali, et al.
Publicado: (2019)

Age and number of organ dysfunctions are associated with early mortality in patients suffering from severe sepsis treated with recombinant human activated protein C
por: Vazquez de Anda, G, et al.
Publicado: (2004)

Dose effects of recombinant human IL-11 on the systemic hemodynamic function in hemorrhagic shock
por: Honma, K, et al.
Publicado: (2007)

Characterization of organophosphate poisoning patients in the ICU: a 4-year review
por: Sá, A, et al.
Publicado: (2009)

CN54gp140: product characteristics, peclinical and clinical use - recombinant glycoprotein for HIV immunization
por: Katinger, D, et al.
Publicado: (2012)

Clinical efficacy of recombinant human soluble thrombomodulin in patients with septic disseminated intravascular coagulation
por: Suzuki, Y, et al.
Publicado: (2013)

P17-27. Development of recombinant adenovirus 28 vectors for HIV vaccines
por: Ko, S, et al.
Publicado: (2009)

Protection against highly pathogenic SIV by BCG-SIV recombinant priming and attenuated replicating vaccinia-SIV recombinant boosting
por: Zhang, X, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ftddbnbu49soptiar1641c5gki